![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
732kB |
![[thumbnail of Supplementary Material]](https://mdc-test.eprints-hosting.org/style/images/fileicons/application_msword.png) |
MS Word (Supplementary Material)
59kB |
| Item Type: | Article |
|---|---|
| Title: | Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network |
| Creators Name: | Greinix, H.T., Attarbaschi, A., Girschikofsky, M., Greil, R., Holter, W., Neumeister, P., Peters, C., Petzer, A., Rudzki, J., Schlenke, P., Schmitt, C.A., Schwinger, W., Wolf, D., Worel, N. and Jaeger, U. |
| Abstract: | Chimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. Known side effects of these approved cellular immunotherapies are cytokine release syndrome, immune-cell associated neurotoxicity syndrome, cytopenias, infections and long-lasting B cell aplasia. Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers. |
| Keywords: | CAR-T Cells, Position Statement, Network, Patient Selection Criteria, Infrastructure Requirements |
| Source: | memo: Magazine of European Medical Oncology |
| ISSN: | 1865-5041 |
| Publisher: | Springer |
| Volume: | 13 |
| Number: | 1 |
| Page Range: | 27-31 |
| Date: | March 2020 |
| Official Publication: | https://doi.org/10.1007/s12254-020-00582-4 |
Repository Staff Only: item control page
